Histone lactylation-induced USP33 upregulation promotes TRAF2 stabilization and scleral remodeling in form-deprivation myopia

Guan, Meng, Li, Jianhua, Wang, Yuanyuan, Cha, Jianmei, Zhang, Boyong
Biology Direct · Springer Nature · 2026-11-18 · DOI: 10.1186/s13062-026-01064-z

Аннотация

Background Scleral remodeling with myofibroblast activation and extracellular matrix (ECM) degradation drives myopia, but mechanisms remain unclear. This study explored USP33’s role and its regulatory network. Methods We analyzed GEO dataset GSE280609 from myopic guinea‑pig sclera. Four‑week‑old male C57BL/6J mice were used for the form‑deprivation myopia (FDM) model, and human scleral fibroblasts (HSFs) were exposed to hypoxia. USP33 was modulated by shRNA or overexpression constructs. Scleral phenotypes, protein interaction, ubiquitination, H3K18la at the USP33 promoter, and quercetin (QE) efficacy were assessed using multiple cellular and molecular assays. Results USP33 was significantly upregulated in myopic sclera and hypoxic HSFs, correlating with enhanced NF-κB-driven inflammation. USP33 knockdown alleviated hypoxia-induced cell injury, myofibroblast activation, ECM remodeling and inflammatory responses in HSFs, while AAV-mediated USP33 knockdown in FDM mice mitigated myopic refractive shift, scleral thinning, collagen loss and inflammation. Mechanistically, USP33 directly bound to TRAF2 via its DUSP1 domain and stabilized TRAF2 protein through K48-linked deubiquitination. Upstream, hypoxia enhanced glycolysis and lactate accumulation, which promoted H3K18 histone lactylation at the USP33 promoter and transcriptionally upregulated USP33. QE suppressed the glycolysis-H3K18la-USP33 axis and alleviated HSF dysfunction and FDM progression, effects that were reversed by USP33 overexpression. However, without axial length and corneal curvature measurements, the observed refractive changes cannot be solely attributed to axial elongation. Conclusion In the FDM mouse model, histone lactylation-driven USP33 upregulation promotes scleral inflammation and remodeling, correlating with myopic refractive shifts; TRAF2 is identified as a candidate USP33 substrate, and QE targeting the glycolysis-H3K18la-USP33 axis represents a preclinical therapeutic candidate. Graphical Abstract Proposed pathway in hypoxic HSFs and a form-deprivation myopia model: increased glycolysis produces lactate, leading to histone lactylation at H3K18la and activity at the USP33 promoter. The pathway links USP33 to TRAF2 deubiquitination, increased NF-kappa B pathway activity, extracellular matrix degradation, and increased myopia. Quercetin inhibits glycolysis.

Читать у издателя →

Похожие статьи